Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.33 |
| ▸ | RELA | Q04206 | 3/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9414132 | 0.89 | NLRP3 (0.38) | NLRP3CYP19A1NFKB1NFKB2RELA | |
| SCHEMBL6439354 | 0.78 | NFKB1 (0.49) | NLRP3CYP19A1NFKB1NFKB2RELA | |
| SCHEMBL2816076 | 0.78 | NFKB1 (0.49) | NLRP3CYP19A1NFKB1NFKB2RELA | |
| SCHEMBL2816078 | 0.78 | NFKB1 (0.49) | NLRP3CYP19A1NFKB1NFKB2RELA | |
| SCHEMBL2541139 | 0.77 | CA12 (0.40) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL2541143 | 0.77 | CA12 (0.40) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL11414567 | 0.75 | CA12 (0.41) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL11414562 | 0.75 | CA12 (0.41) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL11583404 | 0.73 | CYP19A1 (0.39) | CYP19A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL8354298 | 0.72 | CA12 (0.42) | CYP19A1CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9907762-B2 | Stabilized mutant opsin proteins | UNIVERSITY OF WASHINGTON (US) | 2018-03-06 | — | — | US | disclosed |
| US-20160045453-A1 | STABILIZED MUTANT OPSIN PROTEINS | UNIV WASHINGTON (US) | 2016-02-18 | — | — | US | disclosed |
| US-9149446-B2 | Stabilized mutant opsin proteins | UNIVERSITY OF WASHINGTON (US) | 2015-10-06 | — | — | US | disclosed |
| US-20130072443-A1 | STABILIZED MUTANT OPSIN PROTEINS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120041073-A1 | STABILIZED MUTANT OPSIN PROTEINS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2012-02-16 | — | — | US | disclosed |
| US-20040242704-A1 | Stabilized mutant opsin proteins | UNIVERSITY OF WASHINGTON, TECHTRANSFER - INVENTION LICENSING | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242704-A1 | Stabilized mutant opsin proteins | NR2E3, CRYZ, RBP1 | NLRP3 4589/4885CYP19A1 4436/4885NFKB1 4193/4885 |
| US-20160045453-A1 | STABILIZED MUTANT OPSIN PROTEINS | NR2E3, RBP1, CRYZ | NLRP3 4534/4885CYP19A1 4426/4885NFKB1 4563/4885 |
| US-20120041073-A1 | STABILIZED MUTANT OPSIN PROTEINS | NR2E3, CRYZ, RBP1 | NLRP3 4589/4885CYP19A1 4436/4885NFKB1 4193/4885 |
| US-20130072443-A1 | STABILIZED MUTANT OPSIN PROTEINS | NR2E3, CRYZ, RBP1 | NLRP3 4589/4885CYP19A1 4436/4885NFKB1 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.